EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes
N/A
18 Years
80 Years
18 Years
80 Years
Open (Enrolling)
Both
Non Small Cell Lung Cancer
Both
Non Small Cell Lung Cancer
Trial Information
EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes
NSCLC is a common cancer. Accurate and early staging has a significant impact on outcome.
EBUS-TBNA of involved mediastinal lymph nodes is critical. Molecular markers could improve
mediastinal staging.
Inclusion Criteria:
- Age ≥ 18 years
- Samples are collected before surgery or before any therapy
- ECOG 0 or 1
- Clinical stage I-II, T1-2, N0-1, M0)
- Surgically respectable
- Patient with enlarged med. lymphnodes (control group)
Exclusion Criteria:
- Previous RT/CHT
- Previous or current cancer of other entity
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Principal Investigator
Michael Kreuter, MD
Investigator Role:
Study Director
Investigator Affiliation:
Thoraxklinik Heidelberg, Germany
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
MK01
NCT ID:
NCT00982605
Start Date:
October 2009
Completion Date:
January 2011
Related Keywords:
- Non Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
